SCHEDULE: State Street Discloses 5.3% Stake in 4D Molecular Therapeutics

State Street Corporation has reported beneficial ownership of 5.3% of 4D Molecular Therapeutics' common stock as of March 31, 2026.

Summary

• State Street Corporation, through its subsidiaries, has filed a Schedule 13G indicating beneficial ownership of 2,707,875 shares of 4D Molecular Therapeutics' common stock.
• This represents 5.3% of the total class of securities.
• The filing date is March 31, 2026, and the reporting entity is State Street Corporation, a Massachusetts-based financial institution.
• The shares are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a standard disclosure of beneficial ownership by an institutional investor and does not contain operational or financial performance updates.

Future Outlook

No specific forward-looking statements or guidance were provided in this filing.

Industry Context

StockSavvy.ai notes that this Schedule 13G filing by State Street Corporation indicates a significant institutional holding in 4D Molecular Therapeutics, a biotechnology company. Such filings are common for large asset managers and signal their investment positions in publicly traded companies.

Stakeholder Impact

• Shareholders: The filing confirms a substantial institutional holding, which can be viewed positively as it suggests confidence from a major financial institution. However, it does not directly impact current operations or immediate shareholder value.

Key Dates

Keywords

Schedule 13G, State Street Corporation, 4D Molecular Therapeutics, beneficial ownership, common stock, institutional investor, SEC filing